Entrance into Multibillion Dollar Retail and Pharmacy Automation Market
CAVE CREEK, AZ, Feb. 21, 2018 (GLOBE NEWSWIRE) — Endexx Corporation (OTC PINK: EDXC), a provider of innovative phytonutrient-based food and nutritional products, today announced the engagement of Mr. Robert Hasty as the Company’s Senior Advisor to drive commercialization efforts for the Company’s proprietary AutoSpense™ retail technology[D1].
Rob Hasty was formerly Regional Vice President with a top pharmacy retail chain and was responsible for leading all aspects of operations in stores. As Senior Advisor to Endexx, he will spearhead the Company’s proprietary AutoSpense™ technology for implementation into major pharmacy retail chains nationwide.
Endexx recently announced a contract with Impulse Health to launch its AutoSpense™ technology solution allowing Endexx entrance into the retail automation market that is expected to reach $18.99 billion by 2023.
“After 40 years in the retail and pharmacy industry I see AutoSpense™ as a game changer for both the customer and the retailer. Customers have easy access to purchase highly regulated OTC items (such as pseudoephedrine) that they would be unable to in the past improving the customer experience. At the same time the retailer is able to protect high-theft products, reduce shrink which lowers costs of those items and improves operational efficiencies.”
“We are thrilled to have Robert’s expertise and support that we know will ultimately build shareholder value given the huge market opportunity that AutoSpense provides,” said Todd Davis, CEO of Endexx. “Robert knows the ins and outs of the retail and pharmaceutical space which will give us a vital differentiator in the marketplace.”
Endexx, with its collaborative partners and consultants, develops and distributes two consumable product lines derived from industrial hemp, which is organic and naturally rich in phytocannabinoids. Phyto-Bites®, is its CBD-infused soft chews for dogs. The dog treats are formulated to promote health and support the reduction of separation anxiety, pain and inflammation. The company also has two technology products and services that launched in 2014 — the M3hub and the Autospense™. Both products provide essential solutions to promote regulatory compliance and full accountability through “seed to sale” inventory management and an “End of Sale” technology integration. Based on principles developed by the pharmacological industry, the m3hub platform is the first standardized software solution for tracking pharmaceutical grade marijuana that maintains compliance with federal, state and local regulations. It is intended to provide a smooth transition to eventual federal mandates. The Autospense™ is a commercial grade inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security. By automating the dispensing process, Autospense™ increases productivity and reduces costs for marijuana retailers, while enhancing their service quality by reducing transaction time for customers. Websites include: www.cbdunlimited.com, www.endexx.com, www.phytobites.com, www.m3hub.com, www.holisticearthremedies.com.
Safe Harbor Notice
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.
For further investor and media information, contact:
Chairman & CEO